TMCnet News
Ocular Therapeutix™ to Participate in Two Investor Conferences in November 2014BEDFORD, Mass. --(Business Wire)-- Ocular Therapeutix (NASDAQ: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Amar Sawhney, Ph.D., President and Chief Executive Officer, will be presenting at two upcoming investor conferences:
2014 Nomura Biotechnology Conference
2014 Stifel Nicolaus (News - Alert) Healthcare Conference Details of the webcast and a copy of the investor presentation will also be made available in the Investor section of the Corporate website at investors.ocutx.com. About Ocular Therapeutix, Inc. Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix's lead product candidates are in Phase 3 clinical development for post-surgical ocular inflammation and pain, and Phase 2 clinical development for glaucoma and allergic conjunctivitis. The Company is also evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.
|
